Abstract: The primary objective of our study was to evaluate the frequency of suspected heparin-induced thrombocytopenia (HIT) among patients treated with different formulations of heparin and investigate the factors that affect the incidence of HIT. This study is an electronic medical record (EMR)-based large-scale retrospective cohort study conducted from 2009 to 2014 in Korea. After hospitalization, patient platelet count was determined before heparin was prescribed, and all platelet count values obtained during hospitalization were extracted. Suspected HIT was estimated by three 4Ts scores (acute thrombocytopenia, timing onset and other possible causes), which when combined yielded a high probability of HIT. Among 6046 patients enrolled in this study, HIT was suspected in 641 cases (10.6%) and a statistically significant increase in HIT incidence rate was observed for three heparins used (p < 0.001). Dalteparin (HR = 0.55, p = 0.036) and enoxaparin (HR = 0.40, p < 0.001) showed a relatively low HIT incidence rate, compared to unfractionated heparin. Majority of suspected HIT cases (76.9 and 66.7%) occurred in days 8-10 and 5-7 of dalteparin and enoxaparin treatments, respectively. Most of the patients medicated with dalteparin were cancer patients; however, no statistically significant relationship was observed between HIT occurrence and cancer. HIT can cause serious complications, making early diagnosis crucial. Clinical practitioners first prescribing heparin should focus on preventing and detecting complications early by conducting frequent, regular platelet counts before and after heparin administration.
Heparin-induced thrombocytopenia (HIT) occurs in 0.5-5% of patients treated with heparin [1] [2] [3] [4] . The HIT incidence is high in Korea, approximately 1-12% [5, 6] . HIT is an immune disease occurring when HIT antibodies (HIT-Abs) target heparin bound to platelet factor 4 (PF4) [7, 8] . The complex composed of HIT antibodies, heparin and PF4 causes platelet activation leading to thrombocytopenia and thromboembolism. The incidence of HIT depends on the heparin form administered. In patients treated with unfractionated heparin (UFH), HIT develops in 1-3% of the cases and, if accompanied by thrombosis [9, 10] , is followed with the mortality rate of up to 30%. In contrast, the incidence of HIT is <1% when using low-molecular-weight heparin (LMWH). Various complications (deep vein thrombosis, disseminated intravascular coagulation, pulmonary embolism) are the main danger associated with HIT [11, 12] . Therefore, platelet count should be monitored after heparin administration and early diagnosis and prevention of HIT are important. However, diagnosing HIT is not easy, as other causes of thrombocytopenia need to be excluded.
To diagnose HIT in clinical practice, a tissue immunity test against HIT-Abs should be conducted. However, it is impossible to conduct the HIT-Ab test mandatorily on every patient treated with heparin. The 4Ts score is recommended for diagnosing HIT, with high scores indicating a high probability of HIT [3, 13] . The 4Ts score showed similar sensitivity and singularity to the tissue immunity test in diagnosing HIT [13] . Therefore, as conducting the HIT-Ab test is difficult, the 4Ts score should be used more frequently to diagnose HIT with high probability.
Despite the necessity of studying and researching HIT, there is a lack of awareness regarding this condition in Korea; therefore, there is insufficient research concerning HIT incidence or causes. Additionally, although active platelet count and monitoring are required for early detection of HIT, whether a patient has been properly monitored during the clinical phase cannot be clearly ascertained; there are no researches in this regard. Therefore, this study focused on the frequency of highly probable HIT when using 4Ts score among patients treated with different forms of heparin. Additionally, we wanted to confirm whether platelet counts were being monitored properly for early diagnosis of HIT. Moreover, in this study, the incidence of HIT (high probability) was compared between patients treated with UFH and those treated with LMWH, and the factors affecting the incidence of HIT were investigated.
Methods
Study population. This retrospective study was conducted using the information from electronic medical records (EMR) on patients older than 18 years in the Seoul St. Mary's Hospital in Korea from January Author for correspondence: Jang-Yong Kim, Division of Vascular and Transplant Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpodaero, Seocho-gu, Seoul 06591, Korea (e-mail vascularkim@ catholic.ac.kr).
2009 to December 2014. The study included patients who were administered heparin at least once, were hospitalized and who were treated with heparin for over 96 hr. The extracted heparin data covered unfractionated heparin (UFH), dalteparin sodium (dalteparin), enoxaparin sodium (enoxaparin) and nadroparin calcium (nadroparin) treatments. We excluded patients who were previously exposed to heparin, based on documented receipt of heparin within the last year prior to hospitalization. In addition, patients who underwent surgery within 72 hr of heparin administration were excluded. Changes in platelet levels were monitored from the first day of heparin treatment.
Study design. Platelet count was determined before heparin was prescribed after hospitalization, and the study included patients who received the platelet count test once or more after prescription of heparin. All platelet count values obtained during hospitalization were extracted. If platelet levels were determined more than twice a day, the earliest value was used. The dates of the first and last prescriptions of heparin, the daily dosage of heparin, prescription times and any changes in heparins prescribed were recorded. We extracted the patient data, including date of birth, age, gender, height, weight, systolic and diastolic blood pressure, and blood test results: white blood cell (WBC), absolute neutrophil (ANC), red blood cell (RBC) and platelet counts, haemoglobin, haematocrit, prothrombin time (PT), PT-international normalized ratio (PT-INR), and activated partial thromboplastin time (aPTT), blood urea nitrogen (BUN), creatinine, modification of diet in renal disease (MDRD), total bilirubin, aspartate transaminase (AST) and alanine transaminase (ALT) levels, sodium (Na), potassium (K), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).
Definition of HIT. Modified 4Ts scoring was used to evaluate the probability of HIT [13] . 'Acute thrombocytopenia' was defined as the condition with platelet count decrease of >50% since last count and nadir ≥20,000/mm 3 (2 points). Additional 2 points were awarded when the onset timing was between day 5 and day 10 after administration of heparin. Patients diagnosed with other possible causes of thrombocytopenia were given 0 points. Due to the limitations of EMR data, it was impossible to evaluate cases of newly proven thrombosis, but the three scores used (acute thrombocytopenia, timing onset and other causes) provide 6 points combined, which corresponds to high 4Ts score of HIT.
Protection of privacy. This study did not incorporate any interventions or patient examinations or treatment, as it is a cohort study using EMR data to examine the probability of HIT. All information about the subjects, including the registration number and name, was anonymized, and the researchers did not have access to patient personal information. Because of the anonymity of the extracted data and the retrospective nature of the study, informed consent was not required. This study was approved by the institutional review board of the Catholic University of Korea.
Statistical analysis. Continuous and categorical variables were expressed as mean AE standard deviation and numbers with percentages, respectively. Differences in the distribution of patient characteristics were evaluated using the chi-square and independent ttest. HIT-free survival was estimated using the Kaplan-Meier survival curve with the log-rank test. A Cox proportional hazard model was used to evaluate the association between HIT-free survival and the factors of interest. The variables with p value below 0.05 in the univariate analysis were added to a multi-variate model. All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc. Cary, NC, USA). A p < 0.05 was considered statistically significant.
Results
Electronic medical record data indicated that 18,156 patients were over 18 years of age and treated with heparin for the first time ( fig. 1 ). The number of patients receiving UFH was 13,726 (75.6%), whereas 308 (1.7%), 4102 (22.6%) and 20 (0.1%) patients received dalteparin, enoxaparin and nadroparin, respectively. The baseline platelet count of 72 patients was not determined before heparin treatment. As the patients whose platelet count decreased more than 50% in day 1-day 4 period had to be excluded, patients whose platelet count was determined at least twice in day 1-day 4 and day 5-day 10 periods were included in the study because the day 1-day 4 period requires at least one platelet count in patients. For 864, 766 and 2736 patients, platelet count was not determined in day 1-day 10, day 1-day 4 and day 5-day 10 periods, respectively. Therefore, 4438 (24.4%) patients whose platelet counts were insufficiently monitored were excluded. This was the case for 2473 (18%), 149 (48.4%), 1804 (44%) and 12 (60%) patients receiving UFH, dalteparin, enoxaparin and nadroparin, respectively. To determine the possibility of pre-existing thrombocytopenia, patients with baseline platelet count <150,000/lL or >450,000/lL were excluded. In 778 remaining patients (11.6%), the platelet count decreased more than 50% in day 1-day 4 period, leading to their exclusion. The final number of patients included in the study was 5907. Probability of heparin-induced thrombocytopenia. This study examined the probability of HIT in patients treated with heparin for the first time. Among 6046 participating patients, suspected HIT occurred in 641 cases (10.6%), and statistically significant increase of the HIT incidence rate was observed for three heparins (p < 0.001; fig. 2A ). The UFH showed the highest rate of HIT incidence with 13.9% (559 patients), whereas dalteparin and enoxaparin had lower rates of 11.5% (13) and 3.9% (69 patients), respectively. No HIT occurred in nadroparin treatment groups. In multi-variable logistic regression analysis, dalteparin (HR = 0.55, p = 0.036) and enoxaparin (HR = 0.40, p < 0.001) showed relatively low HIT incidence rates, compared to UFH (table 2) . With UFH, HIT equally occurred during the day 5 -day 10 period after the first heparin administration, whereas with dalteparin, the occurring rate was 76.9% (10 patients) in the day 8 -day 10 period and with enoxaparin, the rate was 66.7% (46 patients) in the day 5 -day 7 period (fig. 2B ).
Independent risk factors of HIT according to type of heparin.
To confirm the factors influencing HIT, we analysed the Cox proportion hazard ratio (HR). HIT risk factor analysis indicated that, in patients older than 60 (HR = 0.63, p < 0.001), women had lower hazard ratio compared to men (HR = 0.78, p = 0.002) (table 2). The HR was not significantly different with BMI, BP or comorbidities such as high blood pressure and diabetes. However, the HR of HIT was significant in cancer patients, reaching 1.22 (p = 0.045). Aside from haemoglobin levels influencing HR, no significant difference was observed between the occurrence of HIT and WBC, ANC, Hct, PT-INR, aPTT and glucose levels. In the case of UFH, gender (p = 0.220) and haemoglobin levels (HR = 0.87, p = 0.224) did not significantly affect HIT occurrence (table 3) . The HR of HIT was high (HR = 1.33, p = 0.009) in cancer patients treated with UFH. DBP was the only factor influencing the occurrence of HIT (HR = 0.97, p = 0.018) in enoxaparin treatment. With dalteparin, no factors examined had an effect on HIT occurrence. Most of the patients medicated with dalteparin were cancer patients; however, no statistically significant relationship with cancer was detected. Rather, low HIT occurrence was observed (HR = 0.42, p = 0.404).
Discussion
Heparin-induced thrombocytopenia should be suspected in patients treated with heparin, whose platelet count constantly decreases and who present symptoms of thromboembolism. Multi-organ failure occurs in >50% of HIT patients, leading to 20-30% death rate [14, 15] . Thus, late diagnosis of HIT could be disastrous. As HIT is an immune disease caused by HITAbs [1] , HIT-Abs are used to diagnose it. However, the HITAb test is difficult to conduct on patients, and performing the test on all patients treated with heparin is almost impossible in practice. Therefore, the most important segment of the actual treatment is the clinical diagnosis of the patients by the attending physician. Patient platelet count must be determined before commencing heparin treatment [16] , and a follow-up test after the treatment is recommended. However, this study revealed that in 24.4% of the cases, platelet counts were not monitored during heparin treatment. Considering the fact that high probability of HIT diagnosis was estimated in this study to approximately 10.6% of the cases, a considerable number of HIT patients could be misdiagnosed. In this study, not conducting the required platelet counts was more frequent with LMWH treatments including dalteparin and enoxaparin compared to UFH, likely because medical teams rarely request follow-up platelet counts in LMWH treatments, basing the decision on the fact that HIT occurs less with LMWH, compared to UFH [4] . However, in this study, high-probability HIT diagnosis with dalteparin and enoxaparin was 11.5% and 3.9%, respectively. These findings call for medical teams to monitor platelet counts more closely, to ensure the early discovery of HIT. In addition, it is important to conduct a platelet count in the day 1 -day 5 period, as in 11.6% of the cases, a >50% decrease in platelet count in day 1 -day 4 was observed, which could indicate HIT type I (non-immune heparin-associated thrombocytopenia) [17, 18] . Suspected HIT occurred in 10.6% patients in our study, a high percentage compared to other studies [1] . HIT occurs more in treatment with UFH compared to LMWH [19] . However, in this study, HIT occurrence during UFH treatment was even higher (13.9%). The increase in observed HIT frequency can be partially explained by this study reporting high probability of HIT and not the final diagnosis. Another reason for the apparent high incidence of HIT is that this study is EMR based and may be detecting HIT missed in the clinic. The high-probability HIT occurrence was estimated to be 11.5% and 3.9% for LMWHs dalteparin and enoxaparin, respectively, indicating a difference in HIT occurrence between LMWHs. In addition, the HIT occurrence period depended on the heparin type used in the treatment. With UFH, platelet count HR, Hazard ratio; CI, confidence interval; BMI, body mass index; BP, blood pressure; WBC, white blood cell; ANC, absolute neutrophil count; PT-INR, PT-international normalized ratio; aPTT, activated partial thromboplastin time; BUN, blood urea nitrogen; MDRD, modification of diet in renal disease; AST, aspartate transaminase; ALT, alanine transaminase. Adjusted means of all variables for which p value is below 0.05. Table 3 .
Univariable and multi-variable logistic regression between unfractionated heparin and baseline variables (n = 4030). decreased equally during the day 5 -day 10 treatment period, whereas HIT occurred early with enoxaparin (day 5 -day 7) and late (day 8 -day 10) with dalteparin. Large-scale RCTs are necessary to verify the findings of this study, but we expect that this study will increase the importance of followup platelet counts after heparin administration and help doctors understand which treatment period to focus on when determining the platelet count, depending on the heparin used. Heparin-induced thrombocytopenia occurs more frequently after day 5 of heparin treatment, compared to the day 1 -day 4 period [3] . This study involved patients receiving heparin treatment for more than 4 days, and no correlation between HIT occurrence and diabetes mellitus or high blood pressure was observed. However, HIT occurrence was correlated with cancer. It is also reported that HIT occurs more frequently in women [18, 20] than men, in old men than young men [18, 21] , if underlying diseases are present [22, 23] . However, the findings on the effect of gender on HIT differ from a previous study. Moreover, male patients under the age of 60 years, diagnosed with cancer and with high haemoglobin levels were prone to HIT in our study. Therefore, in our opinion, large-scale studies are necessary. In addition, the risk factor analysis of UFH and LMWH treatments showed very different results, making generalization of findings in table 2 impossible. Instead, only in UFH treatment were age and cancer found to be risk factors for HIT.
Venous thromboembolism (VTE) is a frequent complication in cancer patients [24] . In this study, HIT occurrence was higher in young cancer patients receiving UFH, indicating that LMWHs, including dalteparin and enoxaparin, are better suited for treating cancer patients, in agreement with previous research. Most patients treated with dalteparin in this study had cancer. Dalteparin and enoxaparin previously showed similar compliance, health status, deep venous thrombosis and bleeding rates [25] . Therefore, enoxaparin might be a better choice than dalteparin for treating cancer patients when the probability of HIT is high. If UFH cannot be avoided in treating cancer patients, early detection of HIT should be given more attention.
Our study has some limitations. Firstly, the final diagnosis of HIT should be made based on the results of the HIT-Ab test along with either a decrease in platelet count or clinical signs of thromboembolism [26] ; however, in this study, HIT-Ab test results were unavailable and HIT occurrence was estimated based on the modified 4Ts score. Therefore, as mentioned above, the probability of HIT occurrence, rather than the actual diagnosis was estimated, possibly leading to overestimation. Additional limitations of our study are the inherent limitations of EMR-based retrospective cohorts [27] . There may be unexpected co-factor and confounders that can affect the outcome of the study. For example, we were able to confirm the exposure of heparin through EMR data, but were not able to handle the cases where heparin was prescribed from other hospitals. In order to minimize the co-factors and confounders, researchers included various factors that can be extracted from EMR and established a standardized protocol from the beginning to minimize the problems of EMR-based retrospective cohort study. In addition, the difficulties in determining the prevalence of thrombosis precluded the use of the original 4Ts score. Only three 4Ts factors were evaluated, excluding thrombosis; where the combined score of these factors could reach 6, indicating high-probability HIT, underestimation is likely. Moreover, blood tests were not performed on a daily basis, presenting another possible source of underestimating HIT occurrence rates.
Heparin-induced thrombocytopenia causes serious complications, making early diagnosis crucial. Clinical practitioners first prescribing heparin should focus on preventing and detecting complications early by conducting regular platelet counts before and after heparin administration. As different HIT occurrence rates were observed between LMWH types, heparin treatment should be chosen after considering present underlying diseases and side effects.
